Although there are some concerns regarding DPP-4 inhibitors and breast cancer and its metastasis risk, it seems that both DPP-4 inhibitors and GLP-1 receptor agonists can be considered neutral, or even beneficial (decreased risk of colorectal cancer in case of DPP-4 inhibitors) [99,100,101,102,103,104,105,106,107,108]. The gene discussed is GLP1R; the disease is colorectal cancer.